AMAM - Johnson & Johnson to kick off pharma earnings season amid talc overhang
2024-01-22 12:21:31 ET
More on Johnson & Johnson
- Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
- Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business
- JNJ looking to move talc powder unit to Texas ahead of bankruptcy filing: report
- Anti-obesity meds can expand the market for weight loss surgery: Bernstein